Welcome to our dedicated page for Innate Pharma Marseille SEC filings (Ticker: IPHYF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innate Pharma S.A. filings document foreign private issuer disclosures for a clinical-stage oncology biotechnology company. Its Form 6-K reports furnish press releases on business updates, investor communications, share and voting-right information, and annual general meeting materials.
The filings also describe the company's antibody-engineered immunotherapy portfolio, including IPH4502, lacutamab and monalizumab, along with collaboration references involving AstraZeneca and Sanofi. Governance disclosures include meeting agendas, proposed resolutions, participation and voting mechanics, ordinary and preferred share categories, theoretical and exercisable voting rights, and risk-factor references in its French Universal Registration Document.